Breaking News

ImmunOs Uses ProBioGen’s Pathway Modulator Technology

DirectedLuck transposase technology will be used to increase protein yield of selected candidates in their pipeline of complex recombinant proteins.

By: Contract Pharma

Contract Pharma Staff

ImmunOs Therapeutics will use ProBioGen’s proprietary Pathway Modulator Technology for the development of its pipeline of novel complex recombinant proteins. The Pathway Modulator is based on the stable expression of an optimized key-regulator enzyme acting on multiple pathways involved in cellular protein expression and protein secretion. The combination of ProBioGen’s DirectedLuck transposase technology for high transgene expression and the Pathway Modulator technology boosts the specific ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters